BMJ Analysis Questions the Effectiveness of Obesity Drugs on Quality of Life
A comprehensive analysis published in the British Medical Journal has raised concerns about the effectiveness of popular obesity medications such as Wegovy and Mounjaro. This analysis reviewed 262 randomized controlled trials involving nearly 100,000 participants and found that most obesity drugs do not significantly enhance quality of life. Furthermore, the analysis indicated that only a few of these medications provide cardiovascular benefits after one year of use. This finding is particularly important given that a recent poll by KFF revealed that 45% of adults are interested in safe and effective prescription weight-loss drugs.
The study tracked participants for durations ranging from 12 to 172 weeks, comparing 19 available and emerging obesity drugs against lifestyle changes, placebo, or each other. The average participant was 49 years old, with 63% being female and a body mass index of 35. While the drugs resulted in substantial weight loss, the analysis highlighted significant trade-offs that are often overlooked in marketing materials.
Notably, greater weight loss was associated with increased adverse effects. Participants reported various side effects, including gastrointestinal issues, fatigue, and loss of lean muscle mass. Moreover, the benefits of weight loss appeared to diminish once treatment was discontinued, as trial data indicated that many patients regained a substantial portion of the weight they had lost. For instance, those in the STEP-1 extension study regained approximately two-thirds of their lost weight after stopping the medication. Additionally, a Danish population study found that about half of Wegovy users discontinued the drug within a year, primarily due to side effects or cost concerns.
In terms of weight loss percentages, tirzepatide led to a 14.9% reduction after one year, followed closely by CagriSema at 14.8%, oral semaglutide at 10.9%, and injectable semaglutide at 9.8%. However, the analysis revealed a concerning trend: the more weight a drug helped patients lose, the higher the rates of side effects and dropout, indicating a clear benefit-harm trade-off.
Tirzepatide, for example, resulted in the highest fat mass reduction at 25.7%, but it also caused the most significant loss of lean muscle mass at 8.3%. This is particularly troubling given that maintaining muscle mass is crucial for metabolism, strength, and overall health. Additionally, European regulators have been alerted to reports of suicidal thoughts among users of GLP-1 medications, although a causal link has yet to be confirmed.
The anticipated cardiovascular benefits touted in the media were found to be limited. Only injectable semaglutide demonstrated a reduced risk of death from any cause, heart attack, and heart failure, while tirzepatide showed a 51% reduction in heart-failure risk. However, no other drugs convincingly lowered the risk of kidney failure or provided a meaningful improvement in quality of life.
The researchers acknowledged the limitations of the trials, noting that most had relatively short follow-up periods, which restricts conclusions about long-term safety and effects on heart and kidney health. Additionally, data on several newer drugs were sparse and uncertain, and the trial populations did not necessarily reflect the complexities of real-world patients who often manage multiple health conditions and medications. They emphasized the importance of individualized treatment decisions, weighing expected benefits against potential harms, treatment burdens, costs, and patient preferences.
For the approximately 93 million American adults who qualify for semaglutide, the findings are clear: while weight loss drugs can effectively reduce weight, they do not guarantee improved health, longevity, or enhanced quality of life. The associated muscle loss, gastrointestinal issues, and high dropout rates are critical factors that the pharmaceutical industry may not adequately highlight. Patients deserve comprehensive information about both the benefits and risks to make informed decisions in consultation with their healthcare providers.




